Why the study?
Does epsilon-aminocaproic acid therapy provide sustained antifibrinolytic activity?
Population
Subjects receiving epsilon-aminocaproic acid therapy
Design
Other
Follow-up
3 to 6 days
Authors
Loading...
Short courses of epsilon-aminocaproic acid may fail to sustain antifibrinolytic activity; leaves open optimal dosing strategies for clinical use.
Does epsilon-aminocaproic acid therapy provide sustained antifibrinolytic activity?
Epsilon-aminocaproic acid therapy requires three to six days of continuous administration to achieve sustained fibrinolytic inhibition.
Donald W. Nibbelink (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: